Literature DB >> 317442

Cellular aspects of immunoregulation in malaria.

D J Wyler.   

Abstract

Malaria infection dramatically induces two nonspecific perturbations in immune responsiveness, polyclonal B cell activation and immunosuppression. Polyclonal activation occurs early in infection and results in secretion of antibodies that lack antiplasmodial specificity. Immunosuppression occurs later in infection and is characterized by blunted humoral and cellular immune responses to heterologous (nonplasmodial) as well as plasmodial antigens. Previous studies have suggested that defects in macrophage function may be responsible for immunosuppression in malaria. In what way these cells might be altered in their immunoregulatory role during infection has not been clearly defined. One function of macrophages that is modified in malaria is the ability to secrete in vitro the monokine lymphocyte-activating factor (LAF). Adherent spleen cells obtained from mice early in Plasmodium berghei or P. yoelii infection secrete supernormal amounts of LAF. Adherent cells obtained later in infection show subnormal LAF-secreting activity and secrete an immunosuppressive substance. These modulations in macrophage function may be related to the quantity of parasite material ingested by these cells and might help explain the conversion of macrophages from a helper to a suppressor role in malaria.

Entities:  

Mesh:

Year:  1979        PMID: 317442      PMCID: PMC2395741     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  9 in total

1.  Autoimmune and polyclonal B cell responses during murine malaria.

Authors:  Y J Rosenberg
Journal:  Nature       Date:  1978-07-13       Impact factor: 49.962

2.  Comments on immunization.

Authors:  S Cohen; G A Butcher
Journal:  Mil Med       Date:  1969-09       Impact factor: 1.437

3.  Lymphocyte transformation in human Plasmodium falciparum malaria.

Authors:  D J Wyler; J J Oppenheim
Journal:  J Immunol       Date:  1974-08       Impact factor: 5.422

4.  Influence of malaria infection on the elaboration of soluble mediators by adherent mononuclear cells.

Authors:  D J Wyler; J J Oppenheim; L C Koontz
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

5.  Response of sensitized and unsensitized human lymphocyte subpopulations to Plasmodium falciparum antigens.

Authors:  D J Wyler; H G Herrod; F I Weinbaum
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

6.  Effects of heavy and repeated malarial infections on Gambian infants and children; effects of erythrocytic parasitization.

Authors:  I A MCGREGOR; H M GILLES; J H WALTERS; A H DAVIES; F A PEARSON
Journal:  Br Med J       Date:  1956-09-22

7.  Immunosuppression in murine malaria. I. Response to type III pneumococcal polysaccharide.

Authors:  J S McBride; H S Micklem; J M Ure
Journal:  Immunology       Date:  1977-05       Impact factor: 7.397

8.  Immunity to Plasmodium berghei yoelii in mice. II. Specific and nonspecific cellular and humoral responses during the course of infection.

Authors:  F I Weinbaum; J Weintraub; F K Nkrumah; C B Evans; R E Tigelaar; Y J Rosenberg
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

9.  Malaria antigen-specific T-cell responsiveness during infection with Plasmodium falciparum.

Authors:  D J Wyler; J Brown
Journal:  Clin Exp Immunol       Date:  1977-09       Impact factor: 4.330

  9 in total
  8 in total

1.  Detection of anti-neutrophil cytoplasmic antibodies after acute Plasmodium falciparum malaria.

Authors:  C Wenisch; H Wenisch; H C Bankl; M Exner; W Graninger; S Looareesuwan; H Rumpold
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

2.  Autoantibodies in falciparum malaria: a sequential study in 183 Thai patients.

Authors:  P Phanuphak; S Tirawatnpong; M Hanvanich; W Panmuong; P Moollaor; S Vejjajiva; V Sitprija; R Intaraprasert; D Phanthumkosol
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

3.  Reduced antibody response to the repetitive sequence of the Plasmodium falciparum circumsporozoite protein in mice infected with Plasmodium yoelii blood forms.

Authors:  D Grillot; A Pessi; A S Verdini; P H Lambert; G Del Giudice
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

Review 4.  Malaria: immunity and prospects for vaccination.

Authors:  M Hommel
Journal:  West J Med       Date:  1981-10

5.  Transcription of the tumor necrosis factor alpha gene is rapidly induced by anti-immunoglobulin and blocked by cyclosporin A and FK506 in human B cells.

Authors:  A E Goldfeld; E K Flemington; V A Boussiotis; C M Theodos; R G Titus; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

6.  Antigen-specific B memory cell responses to Plasmodium falciparum malaria antigens and Schistosoma haematobium antigens in co-infected Malian children.

Authors:  Kirsten E Lyke; Amy Wang; Abdoulaye Dabo; Charles Arama; Modibo Daou; Issa Diarra; Christopher V Plowe; Ogobara K Doumbo; Marcelo B Sztein
Journal:  PLoS One       Date:  2012-06-05       Impact factor: 3.240

7.  Correlation of APRIL with production of inflammatory cytokines during acute malaria in the Brazilian Amazon.

Authors:  Raquel A Pinna; Adriana C Dos Santos; Daiana S Perce-da-Silva; Luciene A da Silva; Rodrigo N Rodrigues da Silva; Marcelo R Alves; Fátima Santos; Joseli de Oliveira Ferreira; Josué C Lima-Junior; Déa M Villa-Verde; Paula M De Luca; Carla E Carvalho-Pinto; Dalma M Banic
Journal:  Immun Inflamm Dis       Date:  2018-01-03

8.  Controlled human malaria infection with Plasmodium falciparum demonstrates impact of naturally acquired immunity on virulence gene expression.

Authors:  Anna Bachmann; Ellen Bruske; Ralf Krumkamp; Louise Turner; J Stephan Wichers; Michaela Petter; Jana Held; Michael F Duffy; B Kim Lee Sim; Stephen L Hoffman; Peter G Kremsner; Bertrand Lell; Thomas Lavstsen; Matthias Frank; Benjamin Mordmüller; Egbert Tannich
Journal:  PLoS Pathog       Date:  2019-07-11       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.